All In Biotech

Free tool

FAERS Monitor: Elmiron

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020193 or its brand name (Elmiron, Pentosan Polysulfate Sodium). Reports on generic versions are filed under their own applications.

Reports

6,930

Serious

4,861

70% of reports

Hospitalization

653

Death reported

120

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use1,404
  • maculopathy1,398
  • retinal pigmentation607
  • dry age-related macular degeneration562
  • pigmentary maculopathy470
  • drug ineffective354
  • pain304
  • nausea278
  • product use issue272
  • headache237
  • cystitis interstitial214
  • macular degeneration214
  • diarrhoea208
  • alopecia206
  • fatigue199

Reports by year received

View as table
YearReports
200441
200551
200657
200752
200869
200970
2010112
2011169
2012157
2013146
2014170
2015565
2016355
2017276
2018331
2019334
2020499
2021686
20221,541
2023601
2024331
2025223
202694

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,229 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pigmentary maculopathySignal470118953.867103.71,388,955
retinal pigmentationSignal60710185.38642.01,417,515
dry age-related macular degenerationSignal5623114.72775.5862,148
maculopathySignal1,3981972.11851.51,668,964
cystitis interstitialSignal214465.6404.085,623
macular degenerationSignal21455.448.511,170
off label useSignal1,4044.94.74,498
product use issueSignal2724.43.9716
alopeciaSignal2063.22.8309
pain3041.51.352
headache2371.11.04
nausea2781.11.01
diarrhoea2081.00.90
drug ineffective3540.80.716
fatigue1990.80.713

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.